Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

Experimental & Molecular Medicine
Zhichao LiaoJilong Yang

Abstract

Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a single-arm, nonrandomized phase II study (NCT03121846) to assess the efficacy and safety of apatinib in patients with stage IV sarcoma. We recruited 64 patients with stage IV sarcoma who had failed chemotherapy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were progression-free survival rate (PFR), objective response rate (ORR), and disease control rate (DCR) at week 12. Treatment-related adverse effects (AEs) were evaluated. Fifty-nine patients were assessed for efficacy and 64 patients for AEs. The median PFS was 7.93 months. At 12 weeks, the PFR was 74%, the ORR was 16.95% (10/59), and the DCR was 86.44% (51/59). The final ORR was 15.25% (9/59) and the DCR was 57.63% (34/59). Notably, 22 patients (34.38%) who developed hypertension, hand-foot-skin reaction, or proteinuria had significantly longer OS than those without these AEs (18.20 vs. 10.73 months; P = 0.002). We conclude that apatinib is effective and well tolerated in patients with advanced sarcoma. The development of hypertension, hand-foot-skin reaction, or proteinuria may indicate a favorab...Continue Reading

References

Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martee L HensleyDavid R Spriggs
Dec 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J-Y BlayO S Nielsen
Aug 7, 2003·Seminars in Radiation Oncology·Andy TrottiPhilip Rubin
Sep 3, 2003·Nature Reviews. Cancer·Lee J Helman, Paul Meltzer
Apr 6, 2004·American Journal of Physiology. Lung Cellular and Molecular Physiology·Jen-Ruey TangSteven H Abman
Oct 19, 2005·Cancer Research·Kristin BairdPaul S Meltzer
Dec 27, 2005·Experimental Cell Research·Judah Folkman
May 25, 2006·Current Opinion in Oncology·Lakshmi Balasubramanian, Andrew M Evens
Sep 28, 2007·Investigational New Drugs·Paolo Andrea ZucaliArmando Santoro
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 25, 2009·Current Treatment Options in Oncology·Noah FedermanWilliam D Tap
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne GeorgeMary L Keohan
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert G MakiGary K Schwartz
Oct 15, 2010·Cancer·Antoine ItalianoBinh Bui
May 19, 2012·Lancet·Vivien H C Bramwell
Sep 4, 2012·Lancet·Makoto Endo, Torsten O Nielsen
Oct 6, 2012·Clinical Sarcoma Research·Zachary BurninghamJoshua D Schiffman
Aug 7, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jin LiHao Yu
Mar 8, 2014·International Journal of Cancer. Journal International Du Cancer·Xichun HuChunmei Liao
Apr 11, 2014·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret von MehrenUNKNOWN National Comprehensive Cancer Network
Aug 25, 2015·Pathology, Research and Practice·Eric KampmannThomas Knösel
Jan 23, 2016·Cancer Letters·Giandomenico RovielloDaniele Generali
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
Apr 14, 2016·The Lancet Oncology·Toshirou Nishida, Toshihiko Doi
May 18, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lawrence H SchwartzLesley Seymour
Aug 17, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sheng Zhang
Aug 17, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hyo Jin LeeSeung Woo Baek
Aug 27, 2016·OncoTargets and Therapy·Guanghui JiPing Yang
Jul 6, 2017·Oncotarget·Yong ZhouChongqi Tu
Dec 12, 2017·Biochemical and Biophysical Research Communications·Bingxin ZhengWei Guo

❮ Previous
Next ❯

Citations

Jan 17, 2021·Journal of Cancer Research and Clinical Oncology·Chuanxi ZhengLi Min
Dec 1, 2021·Cancer Control : Journal of the Moffitt Cancer Center·Jin YuanShengji Yu

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03121846
NCT03120846

Software Mentioned

PASS
Statistical Package for the Social Sciences software ( SPSS )

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.